Implication of snoRNA U50 in human breast cancer

Xue-Yuan Dong; Peng Guo; Jeff Boyd; Xiaodong Sun; Qunna Li; Wei Zhou; Jin-Tang Dong

doi:10.1016/S1673-8527(08)60134-4

Volume 36 Issue 8

Aug. 2009

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Genetics and Genomics > 2009 > 36(8): 447-454

PDF( 487 KB)

Implication of snoRNA U50 in human breast cancer

doi: 10.1016/S1673-8527(08)60134-4

a
Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Atlanta, Georgia 30322, USA
b
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA

More Information

Corresponding author: E-mail address: jdong2@emory.edu (Jin-Tang Dong)
Received Date: 2009-03-23
Accepted Date: 2009-04-27
Rev Recd Date: 2009-04-20

Available Online: 2009-08-14

Publish Date: 2009-08-20

Abstract

Abstract

Deletion of chromosome 6q is frequent in breast cancer, and the deletion often involves a region in 6q14-q16. At present, however, theunderlying tumor suppressor gene has not been established. Based on a recent study identifying snoRNA U50 as a candidate for the6q14-16 tumor suppressor gene in prostate cancer, we investigated whether U50 is also involved in breast cancer. PCR-based approachesshowed that U50 underwent frequent genomic deletion and transcriptional downregulation in cell lines derived from breast cancer. Mutation screening identified the same 2-bp deletion of U50 as in prostate cancer in both cell lines and primary tumors from breast cancer, andthe deletion was both somatic and in germline. Genotyping of a cohort of breast cancer cases and controls for the mutation demonstratedthat, while homozygous genotype of the mutation was rare, its heterozygous genotype occurred more frequently in women with breastcancer. Functionally, re-expression of U50 resulted in the inhibition of colony formation in breast cancer cell lines. These results suggestthat noncoding snoRNA U50 plays a role in the development and/or progression of breast cancer.
- snoRNA,
- tumor suppressor gene,
- breast cancer

FullText(HTML)

References(38)

References

[1]	Abdollahi, A., Pisarcik, D., Roberts, D. et al. J. Biol. Chem., 278 (2003),pp. 6041-6049
[2]	Basyuk, E., Coulon, V., Le Digarcher, A. et al. Mol. Cancer Res., 3 (2005),pp. 483-492
[3]	Callahan, R., Campbell, G. Mutations in human breast cancer: An overview J. Natl. Cancer Inst., 81 (1989),pp. 1780-1786
[4]	Cesari, R., Martin, E.S., Calin, G.A. et al. Proc. Natl. Acad. Sci. USA, 100 (2003),pp. 5956-5961
[5]	Devilee, P., van Vliet, M., van Sloun, P. et al. Allelotype of human breast carcinoma: A second major site for loss of heterozygosity is on chromosome 6q Oncogene, 6 (1991),pp. 1705-1711
[6]	Dong, J.T. Chromosomal deletions and tumor suppressor genes in prostate cancer Cancer Metastasis Rev., 20 (2001),pp. 173-193
[7]	Dong, J.T., Chen, C., Stultz, B.G. et al. Deletion at 13q21 is associated with aggressive prostate cancers Cancer Res., 60 (2000),pp. 3880-3883
[8]	Dong, X.Y., Chen, C., Sun, X. et al. Cancer Res., 66 (2006),pp. 6998-7006
[9]	Dong, X.Y., Rodriguez, C., Guo, P. et al. Hum. Mol. Genet., 17 (2008),pp. 1031-1042
[10]	Dutrillaux, B., Gerbault-Seureau, M., Zafrani, B. Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes Cancer Genet. Cytogenet., 49 (1990),pp. 203-217
[11]	Foulkes, W.D., Ragoussis, J., Stamp, G.W. et al. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma Br. J. Cancer, 67 (1993),pp. 551-559
[12]	Gold, B., Kirchhoff, T., Stefanov, S. et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 Proc. Natl. Acad. Sci. USA, 105 (2008),pp. 4340-4345
[13]	Han, W., Han, M.R., Kang, J.J. et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer BMC Cancer, 6 (2006),p. 92
[14]	Kishore, S., Stamm, S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C Science, 311 (2006),pp. 230-232
[15]	Knuutila, S., Aalto, Y., Autio, K. et al. DNA copy number losses in human neoplasms Am. J. Pathol., 155 (1999),pp. 683-694
[16]	Lee, J.H., Kavanagh, J.J., Wildrick, D.M. et al. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas Cancer Res., 50 (1990),pp. 2724-2728
[17]	Li, Y., Huang, J., Zhao, Y.L. et al. Oncogene, 26 (2007),pp. 6220-6228
[18]	Matera, A.G., Terns, R.M., Terns, M.P. Non-coding RNAs: Lessons from the small nuclear and small nucleolar RNAs Nat. Rev. Mol. Cell Biol., 8 (2007),pp. 209-220
[19]	Mattick, J.S. RNA regulation: A new genetics? Nat. Rev. Genet., 5 (2004),pp. 316-323
[20]	Mattick, J.S., Makunin, I.V. Small regulatory RNAs in mammals Hum. Mol. Genet., 14 (2005),pp. R121-R132
[21]	Mertens, F., Johansson, B., Hoglund, M. et al. Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms Cancer Res., 57 (1997),pp. 2765-2780
[22]	Morinaga, N., Shitara, Y., Yanagita, Y. et al. Int. J. Oncol., 17 (2000),pp. 1125-1129
[23]	Mourtada-Maarabouni, M., Pickard, M.R., Hedge, V.L. et al. Oncogene, 28 (2009),pp. 195-208
[24]	Noviello, C., Courjal, F., Theillet, C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: Possibly four regions of deletion Clin. Cancer Res., 2 (1996),pp. 1601-1606
[25]	Orphanos, V., McGown, G., Hey, Y. et al. Proximal 6q, a region showing allele loss in primary breast cancer Br. J. Cancer, 71 (1995),pp. 290-293
[26]	Rodriguez, C., Causse, A., Ursule, E. et al. At least five regions of imbalance on 6q in breast tumors, combining losses and gains Genes Chromosomes Cancer, 27 (2000),pp. 76-84
[27]	Rosa-Rosa, J.M., Pita, G., Urioste, M. et al. Genome- wide linkage scan reveals three putative breast-cancer-susceptibility loci Am. J. Hum. Genet., 84 (2009),pp. 115-122
[28]	Sandhu, A.K., Kaur, G.P., Reddy, D.E. et al. A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells Oncogene, 12 (1996),pp. 247-252
[29]	Schwendel, A., Richard, F., Langreck, H. et al. Chromosome alterations in breast carcinomas: Frequent involvement of DNA losses including chromosomes 4q and 21q Br. J. Cancer, 78 (1998),pp. 806-811
[30]	Seute, A., Sinn, H.P., Schlenk, R.F. et al. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients Int. J. Cancer, 93 (2001),pp. 80-84
[31]	Sheng, Z.M., Marchetti, A., Buttitta, F. et al. Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas Br. J. Cancer, 73 (1996),pp. 144-147
[32]	Smith, C.M., Steitz, J.A. Mol. Cell. Biol., 18 (1998),pp. 6897-6909
[33]	Smith, R.A., Cokkinides, V., Eyre, H.J. Cancer screening in the United States, 2007: A review of current guidelines, practices, and prospects CA. Cancer J. Clin., 57 (2007),pp. 90-104
[34]	Sun, X., Frierson, H.F., Chen, C. et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer Nat. Genet., 37 (2005),pp. 407-412
[35]	Theile, M., Seitz, S., Arnold, W. et al. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer Oncogene, 13 (1996),pp. 677-685
[36]	Varrault, A., Ciani, E., Apiou, F. et al. Proc. Natl. Acad. Sci. USA, 95 (1998),pp. 8835-8840
[37]	Zeller, C., Hinzmann, B., Seitz, S. et al. Oncogene, 22 (2003),pp. 2972-2983
[38]	Zhang, Y., Matthiesen, P., Siebert, R. et al. Hum. Genet., 103 (1998),pp. 727-729

Relative Articles

[1]	Shuyu Liang, Sicheng Xu, Shichong Zhou, Cai Chang, Zhiming Shao, Yuanyuan Wang, Sheng Chen, Yunxia Huang, Yi Guo. IMAGGS: a radiogenomic framework for identifying multi-way associations in breast cancer subtypes[J]. Journal of Genetics and Genomics. doi: 10.1016/j.jgg.2023.09.010
[2]	Min Gao, Kexin Fan, Yuhan Chen, Guangjian Zhang, Jing Chen, Yilei Zhang. Understanding the mechanistic regulation of ferroptosis in cancer: the gene matters[J]. Journal of Genetics and Genomics, 2022, 49(10): 913-926. doi: 10.1016/j.jgg.2022.06.002
[3]	Maxwell Shulman, Rachel Shi, Qing Zhang. Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer[J]. Journal of Genetics and Genomics, 2021, 48(7): 552-559. doi: 10.1016/j.jgg.2021.05.016
[4]	Jian Sun, Wenjing Liu, Yongbo Guo, Hailin Zhang, Dewei Jiang, Ying Luo, Rong Liu, Ceshi Chen. Characterization of tree shrew telomeres and telomerase[J]. Journal of Genetics and Genomics, 2021, 48(7): 631-639. doi: 10.1016/j.jgg.2021.06.004
[5]	Justin Elfman, Lam-Phong Pham, Hui Li. The relationship between chimeric RNAs and gene fusions: Potential implications of reciprocity in cancer[J]. Journal of Genetics and Genomics, 2020, 47(7): 341-348. doi: 10.1016/j.jgg.2020.04.005
[6]	Yang Duan, Xingyan Zhang, Lihong Yang, Xu Dong, Zhanye Zheng, Yiming Cheng, Hao Chen, Bei Lan, Dengwen Li, Jun Zhou, Chenghao Xuan. Disruptor of telomeric silencing 1-like (DOT1L) is involved in breast cancer metastasis via transcriptional regulation of MALAT1 and ZEB2[J]. Journal of Genetics and Genomics, 2019, 46(12): 591-594. doi: 10.1016/j.jgg.2019.11.008
[7]	Ling Lu, Junqin Bi, Liming Bao. Genetic profiling of cancer with circulating tumor DNA analysis[J]. Journal of Genetics and Genomics, 2018, 45(2): 79-85. doi: 10.1016/j.jgg.2017.11.006
[8]	Wei Xie, Yunfan Yang, Siqi Gao, Ting Song, Yuhan Wu, Dengwen Li, Min Liu, Jun Zhou. The tumor suppressor CYLD controls epithelial morphogenesis and homeostasis by regulating mitotic spindle behavior and adherens junction assembly[J]. Journal of Genetics and Genomics, 2017, 44(7): 343-353. doi: 10.1016/j.jgg.2017.06.002
[9]	Dixcy Jaba Sheeba John Mary, Mohan C. Manjegowda, Ajay Kumar, Sarbajeet Dutta, Anil M. Limaye. The role of cystatin A in breast cancer and its functional link with ERα[J]. Journal of Genetics and Genomics, 2017, 44(12): 593-597. doi: 10.1016/j.jgg.2017.10.001
[10]	Zitong Zhao, Xinyi Fan, Lanfang Jiang, Zhongqiu Xu, Liyan Xue, Qimin Zhan, Yongmei Song. miR-503-3p promotes epithelial–mesenchymal transition in breast cancer by directly targeting SMAD2 and E-cadherin[J]. Journal of Genetics and Genomics, 2017, 44(2): 75-84. doi: 10.1016/j.jgg.2016.10.005
[11]	Tatsuo Kido, Yun-Fai Chris Lau. Identification of a TSPY co-expression network associated with DNA hypomethylation and tumor gene expression in somatic cancers[J]. Journal of Genetics and Genomics, 2016, 43(10): 577-585. doi: 10.1016/j.jgg.2016.09.003
[12]	Xufang Deng, Jianchao Wei, Zixue Shi, Wenjun Yan, Zhuanchang Wu, Donghua Shao, Beibei Li, Ke Liu, Xiaodu Wang, Yafeng Qiu, Zhiyong Ma. Tumor suppressor p53 functions as an essential antiviral molecule against Japanese encephalitis virus[J]. Journal of Genetics and Genomics, 2016, 43(12): 709-712. doi: 10.1016/j.jgg.2016.07.002
[13]	Ang Luo, Dan Su, Xuan Zhang, Leilei Qi, Liya Fu, Jin-Tang Dong. Estrogen-estrogen receptor signaling suppresses the transcription of ERRF in breast cancer cells[J]. Journal of Genetics and Genomics, 2016, 43(9): 565-567. doi: 10.1016/j.jgg.2016.06.003
[14]	Zhiqian Zhang, Zhengmao Zhu, Baotong Zhang, Weidong Li, Xin Li, Xiao Wu, Lijuan Wang, Liya Fu, Li Fu, Jin-Tang Dong. Frequent Mutation of rs13281615 and Its Association with PVT1 Expression and Cell Proliferation in Breast Cancer[J]. Journal of Genetics and Genomics, 2014, 41(4): 187-195. doi: 10.1016/j.jgg.2014.03.006
[15]	Masato Enomoto, Tatsushi Igaki. Deciphering tumor-suppressor signaling in flies: Genetic link between Scribble/Dlg/Lgl and the Hippo pathways[J]. Journal of Genetics and Genomics, 2011, 38(10): 461-470. doi: 10.1016/j.jgg.2011.09.005
[16]	Xian-Zong Ye, Shi-Cang Yu, Xiu-Wu Bian. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis[J]. Journal of Genetics and Genomics, 2010, 37(7): 423-430. doi: 10.1016/S1673-8527(09)60061-8
[17]	Sihua Peng, Xiaomin Zeng, Xiaobo Li, Xiaoning Peng, Liangbiao Chen. Multi-class cancer classification through gene expression profiles: microRNA versus mRNA[J]. Journal of Genetics and Genomics, 2009, 36(7): 409-416. doi: 10.1016/S1673-8527(08)60130-7
[18]	Tian Li, Hui Huang, Binlu Huang, Baiqu Huang, Jun Lu. Histone acetyltransferase p300 regulates the expression of human pituitary tumor transforming gene (hPTTG)[J]. Journal of Genetics and Genomics, 2009, 36(6): 335-342. doi: 10.1016/S1673-8527(08)60122-8
[19]	Xinran Xu, Jia Chen. One-carbon metabolism and breast cancer: an epidemiological perspective[J]. Journal of Genetics and Genomics, 2009, 36(4): 203-214. doi: 10.1016/S1673-8527(08)60108-3
[20]	Shenhua Xu, Hangzhou Mou, Linhuei Gu, Dan Su, Chihong Zhu, Xianglin Liu. Screening of the Metastasis-Associated Genes by Gene Chip in High Metastatic Human Ovarian Cancer Cell Lines[J]. Journal of Genetics and Genomics, 2007, 34(7): 581-590. doi: 10.1016/S1673-8527(07)60066-6